QuidelOrtho Sets February 11 for 2025 Full-Year Earnings Release
Event summary
- QuidelOrtho (Nasdaq: QDEL) will report Q4 and full-year 2025 results on February 11, 2026, after market close.
- Conference call scheduled for 2:00 p.m. PT / 5:00 p.m. ET to discuss financial performance.
- Presentation materials and replay available on the Investor Relations page of the company's website.
- QuidelOrtho is a global leader in in vitro diagnostics, spanning clinical chemistry, immunoassay, immunohematology, and molecular testing.
The big picture
QuidelOrtho's earnings release comes at a time when the diagnostics industry is under pressure to deliver cost-effective and accurate solutions. The company's performance will be closely watched as it navigates regulatory changes and competitive dynamics. With a focus on advancing diagnostics across various testing modalities, QuidelOrtho's strategic moves will be critical in maintaining its market position.
What we're watching
- Revenue Trends
- How QuidelOrtho's full-year 2025 revenue compares to previous years and market expectations.
- Market Position
- Whether QuidelOrtho can sustain its leadership in the in vitro diagnostics market amid competitive pressures.
- Innovation Pipeline
- The pace at which QuidelOrtho introduces new diagnostic solutions and their impact on future growth.
Related topics